Hormone therapyFDA-approvedFirst-line
Tamoxifen
How it works
Blocks estrogen receptors on cancer cells, preventing growth signals and inhibiting cell division.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Clinical trials have demonstrated that tamoxifen can improve response rates and progression-free survival in patients with hormone receptor-positive breast cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Tamoxifen and Other Hormone Treatments for Invasive Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Tamoxifen vs Z-Endoxifen in Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Tamoxifen and Omega-3 for Breast Cancer Risk | Breast Cancer | phase-2 | — | Source → |
| Tamoxifen Dose Trial for Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Breast Cancer Prevention Trial | Breast Cancer | phase-2 | — | Source → |
| Tamoxifen Side Effects Linked to Genetic Variants in South African Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Tamoxifen-loaded Nanoparticles Improve Breast Cancer Treatment | Breast Cancer | lab-study | The particles were 6.21-fold more cytotoxic than free tamoxifen. | Source → |
| Tamoxifen Drug Interactions Depend on Genetic Variation and Inhibitor Strength | Breast Cancer | observational | — | Source → |
| Vaginal Tamoxifen May Help Postmenopausal Women with Vaginal Atrophy Symptoms | Breast Cancer | phase-2 | Women on vaginal tamoxifen were more likely to report no or minor symptoms after three months, OR 21.76 (95% CI 7.36 - 64.3). | Source → |
| Tamoxifen Resistance in Breast Cancer: A Key Player Identified | Breast Cancer | lab-study | — | Source → |
| Tamoxifen and Endometrial Health in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Tamoxifen Linked to Uterine Cancer through Non-Genetic Driver | Ovarian Cancer | lab-study | — | Source → |
| Tamoxifen Resistance Overcome with New Cancer Treatment Approach | Breast Cancer | lab-study | — | Source → |
| Tamoxifen Resistance in Breast Cancer: New Insights into Metabolic Changes | Breast Cancer | lab-study | Demethylation restored ASS1 expression and correspondingly reduced tamoxifen IC toward parental levels. | Source → |
| New Nanoparticles Help Target Breast Cancer Cells | Breast Cancer | lab-study | BA@mPEGA FA BSA NPs reduced LCC9 cell IC by 2.29-fold (pH 6.5) versus free BA+TAM. | Source → |
| Genetic Variants Affect Tamoxifen Use in Young Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| USP30's Role in Breast Cancer Progression and Resistance to Tamoxifen | Breast Cancer | lab-study | — | Source → |
| Hormone Therapy Side Effects in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Zeylonone May Help Overcome Tamoxifen Resistance in Breast Cancer | Breast Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.